{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:22:27Z","timestamp":1761844947155,"version":"3.37.3"},"reference-count":41,"publisher":"FapUNIFESP (SciELO)","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"abstract":"<jats:p>SUMMARY  OBJECTIVES  This study aimed at assessing the role of beta-blockers on preventing anthracycline-induced cardiotoxicity in adults.  METHODS  A systematic review was performed on electronic databases, including relevant studies that analysed beta-blockers as cardioprotective agents before the use of anthracyclines by adult oncologic patients.  RESULTS  After application of eligibility and selection criteria, eight articles were considered as high quality, complying with the proposed theme; all eight clinical trials, four of them placebo-controlled, with a total number of 655 patients included. From this sample, 281 (42.9%) used beta-blocker as intervention, and carvedilol was the most frequent (167 patients \u2013 25.5%). Six studies were considered positive regarding the cardioprotection role played by beta-blockers, although only four demonstrated significant difference on left ventricle ejection fraction after chemotherapy on groups that used beta-blockers compared to control groups. Carvedilol and nebivolol, but not metoprolol, had positive results regarding cardioprotection. Other beta-blockers were not analysed in the selected studies.  CONCLUSIONS  Despite the potential cardioprotective effect of beta-blockers, as demonstrated in small and unicentric clinical trials, its routine use on prevention of anthracycline-associated cardiotoxicity demands greater scientific evidence.<\/jats:p>","DOI":"10.1590\/1806-9282.64.08.745","type":"journal-article","created":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T18:12:32Z","timestamp":1543083152000},"page":"745-754","source":"Crossref","is-referenced-by-count":13,"title":["Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers"],"prefix":"10.1590","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6359-2678","authenticated-orcid":false,"given":"Roberto Ramos","family":"Barbosa","sequence":"first","affiliation":[{"name":"School of Sciences of Santa Casa de Miseric\u00f3rdia de Vitoria,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taissa Borges","family":"Bourguignon","sequence":"additional","affiliation":[{"name":"School of Sciences of Santa Casa de Miseric\u00f3rdia de Vitoria,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00edza Dias","family":"Torres","sequence":"additional","affiliation":[{"name":"School of Sciences of Santa Casa de Miseric\u00f3rdia de Vitoria,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza Silveira","family":"Arruda","sequence":"additional","affiliation":[{"name":"School of Sciences of Santa Casa de Miseric\u00f3rdia de Vitoria,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago de Melo","family":"Jacques","sequence":"additional","affiliation":[{"name":"School of Sciences of Santa Casa de Miseric\u00f3rdia de Vitoria,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato Giestas","family":"Serpa","sequence":"additional","affiliation":[{"name":"School of Sciences of Santa Casa de Miseric\u00f3rdia de Vitoria,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osmar de Araujo","family":"Calil","sequence":"additional","affiliation":[{"name":"School of Sciences of Santa Casa de Miseric\u00f3rdia de Vitoria,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Fernando Machado","family":"Barbosa","sequence":"additional","affiliation":[{"name":"School of Sciences of Santa Casa de Miseric\u00f3rdia de Vitoria,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2018,8]]},"reference":[{"issue":"8","key":"ref1","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.10833","article-title":"Childhood cancer survival in Europe and the United States","volume":"95","author":"Gatta G","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"ref2","first-page":"411","article-title":"Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention - review of the literature","volume":"6","author":"Wojtacki J","year":"2000","journal-title":"Med Sci Monit"},{"issue":"9","key":"ref3","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa P","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S0066-782X2011000700001","article-title":"I diretriz brasileira de cardio-oncologia da Sociedade Brasileira de Cardiologia","volume":"96","author":"Kalil Filho R","year":"2011","journal-title":"Arq Bras Cardiol"},{"issue":"6","key":"ref5","first-page":"763","article-title":"Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane","volume":"87","author":"Matos Neto RP","year":"2006","journal-title":"Arq Bras Cardiol"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/fca.12.44","article-title":"Cardiotoxicity in childhood cancer survivors: strategies for prevention and management","volume":"8","author":"Harake D","year":"2012","journal-title":"Future Cardiol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000360238","article-title":"Cardiotoxicity and cardioprotection in childhood cancer","volume":"132","author":"Lipshultz SE","year":"2014","journal-title":"Acta Haematol"},{"issue":"27","key":"ref8","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","journal-title":"Eur Heart J"},{"series-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","author":"Moher D","key":"ref9"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay N","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ajh.21840","article-title":"Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up","volume":"85","author":"Georgakopoulos P","year":"2010","journal-title":"Am J Hematol"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya MG","year":"2013","journal-title":"Int J Cardiol"},{"issue":"23","key":"ref13","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)","volume":"61","author":"Bosch X","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","article-title":"Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up","volume":"21","author":"Elitok A","year":"2014","journal-title":"Cardiol J"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000442722","article-title":"Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial","volume":"134","author":"Tashakori Beheshti A","year":"2016","journal-title":"Cardiology"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4103\/ijmr.IJMR_1323_14","article-title":"Preventive role of carvedilol in adriamycin-induced cardiomyopathy","volume":"144","author":"Jhorawat R","year":"2016","journal-title":"Indian J Med Res"},{"issue":"21","key":"ref17","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati G","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain SM","year":"2003","journal-title":"Cancer"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","article-title":"Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies","volume":"52","author":"Octavia Y","year":"2012","journal-title":"J Mol Cell Cardiol"},{"issue":"7","key":"ref20","first-page":"1789","article-title":"Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis","volume":"60","author":"Arola OJ","year":"2000","journal-title":"Cancer Res"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ctrv.2003.07.003","article-title":"Cardiotoxicity of cytotoxic drugs","volume":"30","author":"Schimmel KJ","year":"2004","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"ref22","first-page":"1277","article-title":"Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin)","volume":"27","author":"Machado V","year":"2008","journal-title":"Rev Port Cardiol"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1527-3466.2001.tb00061.x","article-title":"Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential","volume":"19","author":"Cheng J","year":"2001","journal-title":"Cardiovasc Drug Rev"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.yjmcc.2004.05.024","article-title":"Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro","volume":"37","author":"Spallarossa P","year":"2004","journal-title":"J Mol Cell Cardiol"},{"issue":"8","key":"ref25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cardfail.2012.06.416","article-title":"Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia","volume":"18","author":"El-Shitany AN","year":"2012","journal-title":"J Card Fail"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0167-5273(02)00321-2","article-title":"Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with heart failure (SENIORS). Rationale and design","volume":"86","author":"Shibata MC","year":"2002","journal-title":"Inter J Cardiol"},{"issue":"16","key":"ref27","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacc.2009.05.066","article-title":"Nebivolol: the somewhat-different beta-adrenergic receptor blocker","volume":"54","author":"M\u00fcnzel T","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00005344-200401000-00022","article-title":"Antioxidant activity of nebivolol in the rat aorta","volume":"43","author":"Groot AA","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2007.12.010","article-title":"Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart","volume":"44","author":"Nigris F","year":"2008","journal-title":"Eur J Cancer"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1590\/S0066-782X1998001000008","article-title":"Efic\u00e1cia e tolerabilidade da associa\u00e7\u00e3o bisoprolol\/hidroclorotiazida na hipertens\u00e3o arterial","volume":"71","author":"Luna RL","year":"1998","journal-title":"Arq Bras Cardiol"},{"issue":"11","key":"ref31","first-page":"1669","article-title":"Clinical status and optimal use of the cardioprotectant, dexrazoxane","volume":"11","author":"Blum RH","year":"1997","journal-title":"Oncology"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF01358885","article-title":"Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care","volume":"4","author":"Hellmann K","year":"1996","journal-title":"Support Care Cancer"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11912-010-0129-9","article-title":"Can anthracycline therapy for pediatric malignancies be less cardiotoxic?","volume":"12","author":"Fulbright JM","year":"2010","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00148581-200507020-00001","article-title":"Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management","volume":"7","author":"Iarussi D","year":"2005","journal-title":"Paediatr Drugs"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000265166","article-title":"Doxorubicin cardiomyopathy","volume":"115","author":"Chatterjee K","year":"2010","journal-title":"Cardiology"},{"issue":"7","key":"ref36","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/00003495-200565070-00008","article-title":"Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy","volume":"65","author":"Cvetkovic RS","year":"2005","journal-title":"Drugs"},{"issue":"7","key":"ref37","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/pbc.20488","article-title":"Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography","volume":"45","author":"Paiva MG","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley ML","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt B","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek M","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"ref41","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-017-0938-x","article-title":"SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab","volume":"34","author":"Meattini I","year":"2017","journal-title":"Med Oncol"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0104-42302018000800745&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T03:32:45Z","timestamp":1714707165000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302018000800745&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"alternative-id":["S0104-42302018000800745"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.64.08.745","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"type":"electronic","value":"1806-9282"},{"type":"print","value":"0104-4230"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}